study to assess the safety and tolerability of the Tor Kinase Inhibitor AZD8055

Study identifier:D1600C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, open label, single-centre study to assess the safety and tolerability of the Tor Kinase Inhibitor AZD8055 administered orally to Japanese patients with advanced solid tumours

Medical condition

cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD8055

Sex

All

Actual Enrollment

19

Study type

Interventional

Age

20 Years +

Date

Study Start Date: 01 Aug 2009
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria